Key Insights

Highlights

Treatment Research

1 treatments under study, led by Injection And Infusion Of Lvsmenpdc Vaccine And Antigenspecific Ctls

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04276896Phase 1/2TerminatedPrimary

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Showing all 1 trials

Research Network

Common Treatments

  • Injection And Infusion Of Lvsmenpdc Vaccine And Antigenspecific Ctls1

Active Sponsors

  • Shenzhen Geno-Immune Medical Institute1

Top Investigators

Activity Timeline